Biocon Announces Tentative USFDA Approval for Generic Rifaximin Tablets

Biocon Ltd. has achieved a significant regulatory milestone through its wholly-owned subsidiary, Biocon Pharma Ltd. The company has received tentative approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Rifaximin tablets, 550 mg. Product & Market Opportunity: Drug: Rifaximin is a generic rifamycin antibacterial. Therapeutic Indications: The drug is indicated for two key gastrointestinal conditions in adults: Reducing the risk of overt hepatic encephalopathy (HE) recurrence. Treating irritable bowel syndrome with diarrhea (IBS-D). Significance: This approval marks a critical step towards entering the lucrative U.S. market for this specialty medication. Strategic Implications: This development, achieved in partnership with Carnegie Pharmaceuticals, underscores Biocon's commitment to expanding its complex generics portfolio. It aligns with the management's strategic vision to drive long-term value creation in FY26 and beyond, leveraging its robust business progress and enhanced manufacturing capacities. While tentative approval does not permit immediate commercialization, it signifies that the USFDA has deemed the application approvable pending the resolution of any outstanding patents or exclusivities. This positions Biocon favorably for a potential market launch upon receiving final approval, which would unlock a valuable new revenue stream and strengthen its footprint in the U.S. generics sector. This milestone reinforces the company's R&D capabilities and its ability to navigate complex regulatory pathways for high-value pharmaceutical products.